Millennium Management
XENE icon

Millennium Management’s Xenon Pharmaceuticals XENE Stock Holding History

Millennium Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-45,000
Closed -$1.54M – 6615
2023
Q3 		$1.54M Buy
+45,000
New +$1.68M ﹤0.01% 3817
2021
Q4 		– Sell
-45,000
Closed -$688K – 7457
2021
Q3 		$688K Buy
+45,000
New +$782K ﹤0.01% 5040

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management's XENE Position: Q1 2026 in Review

Millennium Management reduced its Xenon Pharmaceuticals (XENE) stake by 68% in Q1 2026, selling an estimated $20M and leaving 201,785 shares worth $11.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2027.

Millennium Management first reported a position in XENE in Q4 2016 and has held it in 30 quarters since. The position peaked at $55.6M in Q3 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Millennium Management held 201,785 shares of Xenon Pharmaceuticals worth $11.7M as of Q1 2026.
  • Millennium Management sold 433,271 Xenon Pharmaceuticals shares in Q1 2026, an estimated $20M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2027 holding.
  • Millennium Management first reported a position in Xenon Pharmaceuticals in Q4 2016 and has held it in 30 quarters since.
  • Millennium Management's Xenon Pharmaceuticals position peaked at $55.6M in Q3 2025.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.